Cutaneous T-Cell Lymphoma (CTCL)
Symptoms, Doctors, Treatments, Advances & More

Cutaneous T-Cell Lymphoma (CTCL) Overview

Save information for later
Sign Up

Learn About Cutaneous T-Cell Lymphoma (CTCL)

What is the definition of Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known asnon-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sézary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in serious complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown.
What are the alternative names for Cutaneous T-Cell Lymphoma (CTCL)?
  • Cutaneous T-cell lymphoma
  • CTCL
Who are the top Cutaneous T-Cell Lymphoma (CTCL) Local Doctors?
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Larisa Geskin
Oncology
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Larisa Geskin
Oncology
Referral may be required

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave, 
New York, NY 
347-508-2906
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Larisa Geskin is an Oncologist practicing medicine in New York, New York. Dr. Geskin is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.

Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Christiane Querfeld
Dermatology
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Christiane Querfeld
Dermatology
Referral may be required

Christiane Querfeld, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christiane Querfeld is a Dermatologist practicing medicine in Duarte, California. Dr. Querfeld is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Thomas S. Kupper
Dermatology
Elite in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Thomas S. Kupper
Dermatology
Referral may be required

Dana-Farber Cancer Institute, Center For Cutaneous Oncology

450 Brookline Avenue, 
Boston, MA 
617-632-6571
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Kupper is a Dermatologist practicing medicine in Boston, Massachusetts. Dr. Kupper is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Lymphomatoid Papulosis. Dr. Kupper is board certified in Dermatology.

View All Doctors
What are the latest Cutaneous T-Cell Lymphoma (CTCL) Clinical Trials?
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Enrollment Status: Recruiting
Publish Date: June 17, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
Who is this study for: Patients with Recurrent Mycosis Fungoides
Enrollment Status: Recruiting
Publish Date: June 16, 2026
Intervention Type: Biological, Other, Drug
Study Drugs: Durvalumab, Lenalidomide
Study Phase: Phase 1/Phase 2

Summary: This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center